Navigation Links
AVANIR Pharmaceuticals Presents Zenvia Phase III Data in Diabetic,Peripheral Neuropathic Pain at International Congress on,Neuropathic Pain

daily activities (p less than 0.0001), and sleep (p less than 0.0001) compared with placebo.

-- The magnitude of the improvements in quality-of-life with Zenvia treatment was approximately 50% greater than that obtained with placebo (p=0.05 for DM/Q 45 and p=0.08 for DM/Q 30).

-- QTc interval mean change was 5 and 2 milliseconds in the DM/Q 45 and DM/Q 30 treatment groups, respectively compared to the screening visit, versus a mean change in QTc interval of -2 milliseconds for placebo at day 92.

-- There were no cases of Torsade de Pointes (a life-threatening condition) or sudden death reported.

"The Phase III trial data indicate that both doses of Zenvia demonstrated significantly superior reduction of pain compared with placebo in patients with DPN pain. Additionally, Zenvia was generally safe and well tolerated, and safety data were consistent with previous clinical studies with no new safety signals noted," said study investigator Aziz Shaibani, MD, FACP, Clinical Assistant Professor, Department of Medicine, Baylor College of Medicine, Houston, Texas.

"Based on the data from this study, we conclude that Zenvia provides significantly greater improvements compared with placebo in pain-related outcomes in patients with DPN pain, including pain relief, activity and sleep. These are important outcomes to patients suffering from daily pain as a complication of their diabetes," stated Randall Kaye, MD, Chief Medical Officer of AVANIR Pharmaceuticals.

Highlights of Posters

Poster: "EFFICACY AND SAFETY OF DEXTROMETHORPHAN/QUINIDINE IN TREATING PAINFUL DIABETIC PERIPHERAL NEUROPATHY: RESULTS OF A PHASE III, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL," includes:

-- Treatment with Zenvia resulted in a more rapid and marked reduction in pain scores relative to placebo, with a trend toward greater pain reduction at the higher dose.

-- Both active treatment groups had lower pain ratings than placebo patient
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. AVANIR Pharmaceuticals to Present Zenvia Phase III Data in Diabetic Peripheral Neuropathic Pain at Second International Congress on Neuropathic Pain
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
8. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
Post Your Comments:
(Date:12/15/2009)... Today, Hill-Rom Holdings, Inc. (NYSE: ... on significant strategic and financial initiatives at its ... Conference is hosted by Peter H. Soderberg, president ... on the following topics: ,, Status of ... development and financial updates Smart technologies that ...
(Date:12/15/2009)... Rib-X Pharmaceuticals, Inc., a company focused ... drugs for the treatment of serious multi-drug-resistant infections ... research agreement with Massachusetts General Hospital (MGH). ... collaboration, Dr. David Hooper of MGH will evaluate ... model to determine resistance development and to validate ...
(Date:12/15/2009)... SAN DIEGO, INDIANAPOLIS, and CAMBRIDGE, Mass., Dec. 15 ... AMLN ), Eli Lilly and Company (NYSE: ... ALKS ) today announced positive results from ... investigational diabetes therapy, to BYETTA® (exenatide) injection taken ... After 24 weeks of treatment, patients taking exenatide ...
Breaking Medicine Technology:Hill-Rom Investor Conference Features Business Strategy Updates and New Technologies 2Hill-Rom Investor Conference Features Business Strategy Updates and New Technologies 3Hill-Rom Investor Conference Features Business Strategy Updates and New Technologies 4Hill-Rom Investor Conference Features Business Strategy Updates and New Technologies 5Hill-Rom Investor Conference Features Business Strategy Updates and New Technologies 6Hill-Rom Investor Conference Features Business Strategy Updates and New Technologies 7Rib-X Pharmaceuticals Enters into Collaborative Agreement on Delafloxacin with Massachusetts General Hospital 2Rib-X Pharmaceuticals Enters into Collaborative Agreement on Delafloxacin with Massachusetts General Hospital 3Exenatide Once Weekly Provided Superior Glucose Control Compared to BYETTA(R) in DURATION-5 Study 2Exenatide Once Weekly Provided Superior Glucose Control Compared to BYETTA(R) in DURATION-5 Study 3Exenatide Once Weekly Provided Superior Glucose Control Compared to BYETTA(R) in DURATION-5 Study 4Exenatide Once Weekly Provided Superior Glucose Control Compared to BYETTA(R) in DURATION-5 Study 5Exenatide Once Weekly Provided Superior Glucose Control Compared to BYETTA(R) in DURATION-5 Study 6Exenatide Once Weekly Provided Superior Glucose Control Compared to BYETTA(R) in DURATION-5 Study 7First Defense Nasal Screen Comp Releases New Protection Product Just in Time for Pandemic Flu Season 55643 1First Defense Nasal Screen Comp Releases New Protection Product Just in Time for Pandemic Flu Season 55643 2First Defense Nasal Screen Comp Releases New Protection Product Just in Time for Pandemic Flu Season 55643 3First Defense Nasal Screen Comp Releases New Protection Product Just in Time for Pandemic Flu Season 55643 4Waismann Method Offers Safe Treatment for Dependency to Benzodiazepines 55641 1Waismann Method Offers Safe Treatment for Dependency to Benzodiazepines 55641 2Waismann Method Offers Safe Treatment for Dependency to Benzodiazepines 55641 3Watson Pharmaceuticals Receives FDA Approval for Generic PLAN B 28R 29 for Over the Counter Use 55640 1Watson Pharmaceuticals Receives FDA Approval for Generic PLAN B 28R 29 for Over the Counter Use 55640 2
... /PRNewswire/ -- At the April AACR,Annual Meeting, Indivumed ... a new drug test-platform to predict drug,response in ... currently the first,choice for cancer drug testing. During ... protein expression patterns,change significantly, thereby losing many of ...
... 2007 - Insmed Inc.,(Nasdaq:INSM) today announced positive results ... drug, IPLEX(TM), in,patients with myotonic muscular dystrophy (DM1)., ... at,the University of Rochester School of Medicine and ... of IPLEX up to 1,mg/kg/day in six patients ...
Other Medicine Technology:Indivumed Study Provides Sound Scientific Basis for a Predictive,Drug Test- Platform 2Insmed Announces Promising Results From IPLEX Phase II Myotonic,Muscular Dystrophy Clinical Study 2Insmed Announces Promising Results From IPLEX Phase II Myotonic,Muscular Dystrophy Clinical Study 3Insmed Announces Promising Results From IPLEX Phase II Myotonic,Muscular Dystrophy Clinical Study 4
(Date:12/15/2009)... problems must be weighed first, study finds , , TUESDAY, Dec. ... the end-all factor for people with type 2 diabetes who ... degree of blood sugar control in type 2 diabetes "has ... Sheldon Greenfield, a professor of medicine at the University of ... the Dec. 15 issue of the Annals of Internal ...
(Date:12/15/2009)... At a time when Americans spend over $50 billion ... Raymond Hall is theorizing a painful connection between conventional ... called Pillo1 ( www.pillo1.com ) to address the problem. ... John,s Medical Plaza Sleep Disorders Center showed that Pillo1 ... position and promotes increased time spent in REM (rapid ...
(Date:12/15/2009)... For. , ... Alpharetta, GA (Vocus) Dec. 14, 2009 ... temporary physician and CRNA staffing, as the #4 Best Staffing Firm ... ,“We are proud to be recognized on this list because it ... R. Shane Jackson president of LocumTenens.com. “Unquestionably, we know that our ...
(Date:12/15/2009)... will require that certain businesses with large areas where people ... readily available. Fire and rescue personnel agree that for any ... investment. , ... Issaquah, WA (PRWEB) ... require that certain businesses with large areas where people gather, ...
(Date:12/15/2009)... the Dec. 15 issue of the Journal ... associations exist between parent-reported insomnia symptoms and medical ... school-aged children. , Results of multivariate regression ... more likely in children with gastrointestinal regurgitation and ... Nineteen percent of children met the criteria ...
Breaking Medicine News(10 mins):Health News:Tighter Blood Sugar Control Not Best for Some Diabetics 2Health News:Tighter Blood Sugar Control Not Best for Some Diabetics 3Health News:Sleep Study Shows Pillo1 Re-Educates Body to Naturally Move Into Optimal Sleep Position and Increases REM Sleep by 21.3% 2Health News:LocumTenens.com Named 4th Best Staffing Firm to Work For 2Health News:QuickMedical Responds to Oregon Bill Requiring Businesses to Carry Defibrillators 2Health News:QuickMedical Responds to Oregon Bill Requiring Businesses to Carry Defibrillators 3Health News:Insomnia symptoms linked with medical complaints in young school-aged children 2Health News:Insomnia symptoms linked with medical complaints in young school-aged children 3
... "TOGETHER ... HIV STOPS WITH US",is the ... in areas across,the country including: Boston, Long Beach ... real HIV positive people, and a,wide spectrum of ... members,friends, care providers and partners talking about real ...
... often, it reduces bleeding problems, study finds , , MONDAY, Aug. ... from the wrist rather than the groin reduces the incidence ... The approach, using the radial artery in the wrist, is ... analysis of almost 600,000 catheterizations in a national database, said ...
... LOS ANGELES, Aug. 18 Today a representative ... Term Care Workers, Local,6434 ("ULTCW") filed a letter ... ("UHW-W")., In the letter written to President ... -- an elected Vice President of ULTCW and,member ...
... PALO ALTO, Calif., Aug. 18 Based on ... & Sullivan presents ConforMIS,with the 2008 North American ... This recognition is in support of the company,s,unique ... each,individual unlike traditional implants that require surgeons to ...
... In up to 20 percent of people infected with ... and cross into the brain, resulting in HIV-associated dementia ... Einstein College of Medicine of Yeshiva University have found ... of intestinal bacteriaa chemical present in high levels in ...
... Market Intelligence and Competitive Analysis from, Thomson Reuters ... LONDON and PHILADELPHIA, Aug. 18 Thomson ... businesses and,professionals, has announced the availability of the ... Launched more than two years,ago, the quarterly Pharma ...
Other Medicine News:Health News:New HIV Prevention/Anti-Stigma Campaign Featuring HIV Positive & Negative Persons 'TOGETHER' Launches Across the Nation 2Health News:Reaching the Heart Through the Wrist 2Health News:Reaching the Heart Through the Wrist 3Health News:Frost & Sullivan Honors ConforMIS for Its Contribution to Personalized Care Through its Customized Implant Development Technologies 2Health News:Frost & Sullivan Honors ConforMIS for Its Contribution to Personalized Care Through its Customized Implant Development Technologies 3Health News:Frost & Sullivan Honors ConforMIS for Its Contribution to Personalized Care Through its Customized Implant Development Technologies 4Health News:Chemical liberated by leaky gut may allow HIV to infect the brain, Einstein scientists find 2Health News:Chemical liberated by leaky gut may allow HIV to infect the brain, Einstein scientists find 3Health News:Chemical liberated by leaky gut may allow HIV to infect the brain, Einstein scientists find 4Health News:The Scientific Business of Thomson Reuters Publishes Three Pharma Matters Reports Covering the First Quarter of 2008 2Health News:The Scientific Business of Thomson Reuters Publishes Three Pharma Matters Reports Covering the First Quarter of 2008 3
Enzyme Immunoassay of Protein C Antigenby ELISA Method, 96 tests...
Substrate Plasma for Factor II Assay by STA© Analyzers. Freeze-dried human serum and absorbed bovine plasma, the latter providing factor V and fibrinogen to the test system....
Substrate Plasma for Factor IX Assay by STA© Analyzers. Freeze-dried human plasma from which factor IX has been removed by selective immuno-adsorption....
Colorimetric Assay of Plasminogen Activity by STA© Analyzers....
Medicine Products: